These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31005849)

  • 1. Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols.
    Gascón P; Krendyukov A; Mathieson N; Aapro M
    Leuk Res; 2019 Jun; 81():35-42. PubMed ID: 31005849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
    Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.
    Aslaner Ak M; Gedük A; Acar İH; Polat MG; Sunu C; Bolaman AZ; Hacıbekiroğlu T; Güvenç B; Ertop Ş
    Turk J Haematol; 2023 May; 40(2):92-100. PubMed ID: 36799095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
    Park S; Greenberg P; Yucel A; Farmer C; O'Neill F; De Oliveira Brandao C; Fenaux P
    Br J Haematol; 2019 Jan; 184(2):134-160. PubMed ID: 30549002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
    Kelaidi C; Fenaux P
    Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
    Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
    Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.
    Ludwig H; Fritz E
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):35-8. PubMed ID: 9671328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience.
    Gascón P; Goldsmith D; Aapro M; Dellanna F; Esmael A; Zabransky M
    Crit Rev Oncol Hematol; 2023 Jan; 181():103894. PubMed ID: 36481307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
    Shah HH; Fishbane S
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience.
    Dellanna F; Goldsmith D; Krendyukov A; Seidl A; Höbel N; Combe C
    Drug Des Devel Ther; 2018; 12():9-14. PubMed ID: 29296077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin alfa: into the new millennium.
    Adamson JW
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):76-9. PubMed ID: 9671336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes.
    Casadevall N
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):12-8. PubMed ID: 9671324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia of hematologic malignancies: what are the treatment options?
    Ludwig H
    Semin Oncol; 2002 Jun; 29(3 Suppl 8):45-54. PubMed ID: 12082654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study.
    Qu WY; Zhao L; Tan XC; Zhao YH
    Ann Hematol; 2021 Jun; 100(6):1451-1457. PubMed ID: 33837816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.
    Fenaux P; Santini V; Spiriti MAA; Giagounidis A; Schlag R; Radinoff A; Gercheva-Kyuchukova L; Anagnostopoulos A; Oliva EN; Symeonidis A; Berger MH; Götze KS; Potamianou A; Haralampiev H; Wapenaar R; Milionis I; Platzbecker U
    Leukemia; 2018 Dec; 32(12):2648-2658. PubMed ID: 29895954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
    Castelli R; Schiavon R; Rossi V; Deliliers GL
    Med Oncol; 2018 Apr; 35(5):76. PubMed ID: 29675620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia.
    Henry DH
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):64-8. PubMed ID: 9671334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
    Castelli R; Deliliers GL; Colombo R; Moreo G; Gallipoli P; Pantaleo G
    Ann Hematol; 2014 Sep; 93(9):1523-9. PubMed ID: 24711171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.